Jump to content
helplinedonate
  • Announcements

    • ForumAdmin

      Frequently Asked Questions - Step by step guides

      Do you need assistance registering, logging in, posting, etc? Please visit the all new Frequently Asked Question Forum for step-by-step guides. Click the link below to access these helpful guides. Frequently Asked Questions
    • ForumAdmin

      Recursos Nuevos en Español

      http://www.parkinson.org/ayuda   http://www.parkinson.org/espanol    
    • ForumAdmin

      Línea de Ayuda 1-800-473-4636

      Línea de Ayuda 1-800-473-4636   ¿Qué es la línea de ayuda 1-800-4PD-INFO (473-4636) de la Fundación Nacional de Parkinson? Es un número de teléfono gratuito que ayuda a las personas con la enfermedad de Parkinson, sus familiares, amigos y profesionales de salud, a solucionar diferentes inquietudes.   La línea de ayuda ofrece: Información actualizada Apoyo emocional Referidos a profesionales de salud Recursos comunitarios Amplia variedad de publicaciones gratis    
Sign in to follow this  
Dr. Okun

Post of the Week: Update of Azilect FDA Hearing

Recommended Posts

Dr. Okun    409

Dear forum members,

 

We posted this to the main NPF page this week:

 

FDA Reviews Azilect, NPF Participates in Hearing

 

Release date: 10/17/2011

An Advisory Committee to the Food and Drug Administration (FDA) voted against approving a submission by Teva Pharmaceuticals requesting permission to change the way that they describe the benefits of their drug Azilect (rasagiline). Azilect is currently approved to treat the symptoms of Parkinson’s disease; however Teva had requested approval to be able to also say that the drug, “slows clinical progression of Parkinson’s.”

What this means for patients

Dr. Michael Okun, NPF’s National Medical Director, says, “The FDA has met but not ruled as to whether they believe Azilect slows Parkinson's disease progression. Based on the vote of the advisory panel, it is unlikely FDA will approve the request. We will update the PD community as soon as there has been a ruling. I do not believe that the outcome of this hearing should change the immediate management of any PD patient, but if you are concerned we recommend you talk to your doctor.”

NPF joined with the other major PD organizations to issue a joint statement. The joint statement offers support for FDA’s evaluation of the science, and asks FDA to explain the criteria it will use in evaluating whether a drug or therapy slows Parkinson’s disease. We all hope that some of the studies going on right now will achieve that goal. In addition, Joyce Oberdorf, CEO of NPF, addressed how our Quality Improvement Initiative (QII) is helping us to understand the challenges we face in treating Parkinson’s.

NPF will update the Parkinson’s community with any developments.

Share this post


Link to post
Share on other sites
Sign in to follow this  

×